Researchers reviewed the phase 3 findings of a TKI inhibitor treatment compared with aflibercept 2 mg for maintaining vision in patients with wet AMD.

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining the positive topline results from our SOL-1 Phase III clinical trial of AXPAXLI, ...

The MarketWatch News Department was not involved in the creation of this content. Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class ...

New research highlights progress in treating age-related macular degeneration, including late‑stage drug trials, gene therapy strategies, and a wireless retinal prosthesis that restored limited ...

Please provide your email address to receive an email when new articles are posted on . The average number of annual injections decreased from 8.7 in year 1 to 4.7 in year 7. The regimen could reduce ...

Tolerability of VLTR-559 assessed at the anticipated clinical dose for less frequent dosing Positive safety results observed across multiple measures of eye health, including intraocular pressure and ...

MARINA Trial (2006) Ranibizumab is effective in wet AMD (minimal adverse effects) Randomized trial resulted in FDA approval of ranibizumab, the current first-line treatment for wet AMD ANCHOR Trial ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. In recent years, we’ve seen the emergence ...

AXPAXLI (TM) (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic ...